Core Viewpoint - Zhejiang Haisheng Medical Equipment Co., Ltd. is preparing for an IPO on the Beijing Stock Exchange, focusing on the development, production, and sales of anesthesia and monitoring medical devices, with a significant market presence and a gross margin exceeding 50% [1][2]. Financial Performance - The company reported net profits attributable to the parent company of 75.11 million yuan and 68.04 million yuan for 2023 and 2024, respectively [2]. - Total assets increased from 319.68 million yuan in 2022 to 519.45 million yuan by June 30, 2025, indicating a growth trend [3]. - The company's gross margin for the reporting periods was consistently above 50%, with specific figures of 52.84%, 53.15%, 52.07%, and 51.56% [4]. Sales and Revenue - The company’s sales revenue from anesthesia consumables and monitoring products accounted for 48.51% and 38.80% of total revenue in the respective periods [3]. - The sales revenue from the "two-invoice system" was relatively low, contributing only 2.78% to 3.30% of total revenue across the reporting periods [8]. - Concentrated procurement sales revenue was 30.30 million yuan, 34.88 million yuan, and 46.88 million yuan for the years 2023, 2024, and 2025, respectively, representing 11.34% to 16.20% of total revenue [8]. Inventory and Accounts Receivable - The company's inventory value increased from 52.63 million yuan in 2022 to 41.64 million yuan in 2025, reflecting an upward trend as the business scales [5]. - Accounts receivable also rose, indicating a potential for sustained revenue growth, with values of 24.85 million yuan in 2022 and 32.88 million yuan in 2025 [5]. Research and Development - The company is investing in R&D for new medical devices, with ongoing projects for a research and marketing service base and headquarters, with a budget of 243 million yuan [6][7]. Customer Base and Distribution - The company relies heavily on a network of distributors, with 90.43% of revenue coming from distribution sales, and has a total of 919 distributors [13]. - The largest customer, Guangzhou Rongsheng Medical Equipment Co., Ltd., accounted for 8.09% of total revenue in the first half of 2025, indicating a concentration risk [13]. Sales Expenses - Sales expenses as a percentage of revenue were higher than the industry average, at 10.63% in the first half of 2025, compared to an average of 6.25% for comparable companies [16][17]. - The company’s sales expenses are primarily driven by employee compensation, promotional activities, and travel expenses [16]. Regulatory Environment - The impact of policies such as "two-invoice system" and "centralized procurement" on the company's operations is limited, as the company primarily deals with low-value medical devices [8][12].

Core Viewpoint - The pharmaceutical distribution industry in China is undergoing significant changes due to policy reforms, with Guangdong Rontai Pharmaceutical Co., Ltd. (Rontai Pharma) facing multiple challenges as it seeks to go public on the Hong Kong Stock Exchange [1][2]. Industry Overview - The implementation of the two-invoice system and the normalization of volume-based procurement have significantly compressed drug price margins, driving a trend towards prescription outflow [2]. - Major national players like China National Pharmaceutical Group, Shanghai Pharmaceuticals, China Resources Pharmaceutical, and Jiuzhoutong have captured 45.76% of the market share, highlighting the increasing concentration in the industry [2]. Company Positioning - Rontai Pharma ranks as the fourth largest provider of marketing and supply chain solutions in China's outpatient pharmaceutical market, and it holds the top position in the segment targeting individual customers [2]. - Despite its ranking, Rontai Pharma's market share is only 1.2%, which is significantly lower than the leading companies [2]. Financial Performance - Revenue is projected to grow from 2.427 billion yuan in 2022 to 2.875 billion yuan in 2024, reflecting a compound annual growth rate of 8.8% [3]. - However, net profit is expected to decline sharply from 14.78 million yuan to 3.74 million yuan, a decrease of nearly 75% [3]. - The overall gross margin has decreased from 7.6% in 2022 to 6% in 2024, indicating declining profitability compared to competitors [3]. Operational Efficiency - Rontai Pharma's debt-to-asset ratio reached 70% as of June 30, 2025, significantly exceeding healthy industry levels [4]. - The company has a short-term debt of 5.18 billion yuan, while cash and cash equivalents stand at only 1.16 billion yuan, indicating a short-term repayment gap of nearly 400 million yuan [4]. - Operating cash flow has been negative, with a cumulative outflow of 519 million yuan from 2022 to the first half of 2025, suggesting poor cash management [4]. Business Model Challenges - Rontai Pharma's business model relies heavily on third-party e-commerce platforms, which account for 56% of its revenue, limiting its control over customer interactions [7]. - The company faces competition from upstream pharmaceutical companies building their own digital marketing systems and downstream e-commerce platforms extending their reach [7]. Valuation and Investor Sentiment - The company's valuation before its IPO was 2.67 billion yuan, with a price-to-sales ratio of less than 1, significantly below the industry average of 1.5-2 [8]. - Early investors have begun to reduce their stakes, which may indicate a lack of confidence in the company's future performance [8]. Governance and Related Party Transactions - The management team has connections to Kangzhe Group, raising questions about the fairness of related party transactions, which have involved significant procurement amounts [8].

Core Viewpoint - Jianfa Zhixin Medical Technology Group Co., Ltd. officially listed on the Shenzhen Stock Exchange's Growth Enterprise Market, with a stock price surge of over 550% on the first day, reflecting strong market interest and potential growth in the medical device sector [1]. Company Overview - Jianfa Zhixin, a subsidiary of Xiamen Jianfa Group, focuses on the direct sales and distribution of medical devices, providing centralized operation services for medical consumables to hospitals [1]. - The company reported a revenue growth from 11.882 billion yuan in 2022 to 17.923 billion yuan in 2024, with a compound annual growth rate (CAGR) of 22.81% [1]. - Net profit is projected to reach 274 million yuan in 2024, showing a CAGR of over 20% from 189 million yuan in 2022, indicating strong adaptability to industry policies [1]. Market Positioning - Jianfa Zhixin differentiates itself in the competitive medical device market by focusing on high-value medical consumables, establishing itself as a comprehensive service provider in the supply chain [3]. - The company has established partnerships with over 100 well-known medical device manufacturers, providing services to more than 3,300 medical institutions across 31 provinces in China [4]. Product and Service Strategy - The company maintains a "core + diversified" product strategy, focusing on vascular intervention and expanding into surgical instruments and in vitro diagnostics (IVD) [5]. - Revenue from direct sales accounted for approximately 65.71% in 2022, while distribution and service business revenues are also growing, indicating a balanced revenue model [5]. SPD Service Innovation - Jianfa Zhixin's SPD (Supply Chain Management) service is a key innovation, providing centralized management of medical consumables, which significantly reduces inventory costs for hospitals [7]. - The penetration rate of SPD services in public hospitals is currently at 15.29%, indicating substantial growth potential in the market [7]. - The company has signed contracts for SPD services with 60 hospitals, managing over 10 billion yuan in medical consumables by 2024 [7]. Competitive Advantages - Compared to independent SPD service platforms, Jianfa Zhixin benefits from brand strength, financial resources, risk control capabilities, and integrated supply chain management [8]. - The company's focus on understanding hospital needs and investing in technology development enhances its competitive edge and customer loyalty [8].

上海建发致新医疗科技集团 股份有限公司 （上海市杨浦区杨树浦路 288 号 9 层） 首次公开发行股票并在创业板上市 之 上市公告书 保荐人（主承销商） （广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座） 二〇二五年九月 股票简称：建发致新 股票代码：301584 上海建发致新医疗科技集团股份有限公司 上市公告书 特别提示 上海建发致新医疗科技集团股份有限公司（以下简称"建发致新"、"本公司"、 "公司"或"发行人"）股票将于 2025 年 9 月 25 日在深圳证券交易所上市。 创业板公司具有业绩不稳定、经营风险高、退市风险高等特点，投资者面临较大的 市场风险。投资者应充分了解创业板市场的投资风险及本公司所披露的风险因素，审慎 作出投资决定。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新股上市 初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 如无特别说明，本上市公告书中的简称或名词释义与《上海建发致新医疗科技集团 股份有限公司首次公开发行股票并在创业板上市招股说明书》（以下简称"招股说明书"） 中的相同。如本上市公告书中合计数与各加数直接相加之和在尾数上存在差异，系由于 ...

本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创业板公 司具有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成长期、经营风 险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应充 分了解创业板市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 上海建发致新医疗科技集团 股份有限公司 Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. （上海市杨浦区杨树浦路 288 号 9 层） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 上海建发致新医疗科技集团股份有限公司 首次公开发行股票并在创业板上市招股说明书 公司作为全国性的高值医疗器械流通商，主要从事医疗器械直销及分销业务，并 为终端医院提供医用耗材集约化运营（SPD）等服务。经过多年的发展，公司深入研 究传统器械流通业务开展过程中的痛点和挖掘产业链上下游各环节的需求，积极探索 行业变革方向，积累了丰富的业务运营及服务经验，在医疗器械流通领域拥有一定市 场地位。 报告期内，公司业务 ...

首次公开发行股票并在创业板上市 招股意向书 保荐人（主承销商） 司具有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成长期、经营风 险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应充 分了解创业板市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 上海建发致新医疗科技集团 股份有限公司 Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. （上海市杨浦区杨树浦路 288 号 9 层） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创业板公 上海建发致新医疗科技集团股份有限公司 首次公开发行股票并在创业板上市招股意向书 公司已经根据《公司法》《证券法》《上市公司章程指引》，制定了《公司章 程》、三会议事规则、各专门委员会的工作细则、《独立董事工作制度》《董事会秘 书工作细则》，设立了多层次公司治理机构，上述公司治理机构运行、履职情况良好。 公司充分发挥信息系统管理优势，通过自主开发的信息系统整合业务、财务等经 营各环节数据，实现了运营数据的互联 ...

Group 1 - The company plans to issue A-shares to specific investors, pending approval from the Shenzhen Stock Exchange and the China Securities Regulatory Commission (CSRC) [2][3][4] - The final issuance price will be no less than 85% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [3][4][5] - The total number of shares to be issued will not exceed 25% of the company's total share capital, amounting to a maximum of 83,530,821 shares [5][6] Group 2 - The funds raised will be allocated to specific projects, including the construction of a production base for amino acids and an enhancement project for raw materials [6][7] - The company may adjust the investment priorities and amounts based on the actual net amount raised and project urgency if the net proceeds are less than planned [6][7] - The company has committed to using the raised funds in compliance with relevant regulations and will replace any pre-invested funds once the raised funds are available [6][7] Group 3 - The company operates in the pharmaceutical industry, which is subject to strict regulatory oversight from various government bodies, including the National Medical Products Administration and the National Healthcare Security Administration [19][20] - The pharmaceutical industry is characterized by significant competition and regulatory challenges, including drug approval processes and pricing regulations [19][20][21] - The company’s business encompasses pharmaceutical distribution, manufacturing, and health services, with a focus on both commercial and industrial sectors [19][20]

Core Viewpoint - The company aims to become an internationally leading provider of comprehensive blood purification solutions, focusing on the research, production, and sales of medical products related to blood purification [4][14]. Business Operations - The company's main business is centered around the research, production, and sales of blood purification medical products, including blood dialysis machines, blood dialysis tubes, and peritoneal dialysis solutions, making it one of the most comprehensive manufacturers in China [4]. - The sales model combines direct sales and distribution, primarily relying on a large network of distributors across China, covering over 6,000 hospitals and dialysis centers, including more than 1,000 tertiary hospitals [5]. - The company has established joint ventures with international firms to introduce leading technologies and management practices in blood dialysis [6]. Financial Performance - The company's main business revenue consistently accounts for over 95%, with reported revenues of 3.29 billion, 3.45 billion, and 3.53 billion yuan for the years 2022, 2023, and 2024, respectively [9]. - The overall gross margin for the company was 42.91%, 43.74%, and 42.29% across the same periods, with the gross margin for main business products being 44.02%, 44.25%, and 42.73% [10]. - Research and development expenses were reported at 182.84 million, 154.86 million, and 164.70 million yuan, totaling over 500 million yuan during the reporting period [11]. Market Position and Strategy - The company holds a market share of 32.5% in the blood dialysis device sector, 31.8% in blood dialysis tubes, and 24.6% in blood dialysis machines, ranking first and second in their respective categories [22]. - Future strategies include enhancing production capacity, improving quality assurance systems, and increasing research and development investments to maintain market leadership [14][15]. - The company plans to expand its international market presence, with overseas sales of blood dialysis devices reaching 143.60 million yuan, nearly tripling from 2022 [17]. Industry Insights - The blood dialysis industry has high entry barriers due to strict regulations and standards for medical devices, particularly for Class III medical devices [21]. - Key growth drivers for the industry include the increasing number of ESRD patients due to aging populations, improved healthcare payment capabilities, and enhanced insurance systems [21]. - The blood dialysis medical device market in China is projected to grow at a compound annual growth rate of 5.67%, reaching a market size of 51.51 billion yuan by 2030 [21]. Fundraising and Investment - The company plans to issue 41.14 million shares, accounting for 10% of the total post-issue share capital, with all proceeds directed towards projects that align with its core business [25][26]. - The fundraising will support the establishment of intelligent production facilities, a new production line for dialysis devices, and a research center for high-performance blood purification products [26][27]. - A digital information technology platform will be developed to enhance operational efficiency across various business functions [28].

文/西风 近日，深交所公布对赛克赛斯生物科技股份有限公司主板IPO终止审核的决定，直接原因是公司及保荐机构海通证券撤回申报。公司IPO于 2023年2月23日获得受 理，2023年5月23日公布首轮问询的回复，2023年12月30日公布首轮问询回复的更新版。2024年6月29日公布最新版本的招股书（申报稿）。公司本次IPO拟募资 4.55亿元。 公司注册地山东济南，前身山东赛克赛斯药业科技有限公司成立于2003年6月，2018年11月整体变更为股份公司，目前注册资本3.5008亿元。公司控股股东为山东 赛星控股集团有限公司，实际控制人为1977年出生的邹方明先生，拥有美国境外永久居留权。邹方明直接和间接合计控制公司 90.94%的股权，现任公司董事长。 一、2个产品技术水平国际先进，1个产品市占率第一 公司为一家专业从事植介入生物材料类医疗器械的研发、生产和销售的高新技术企业，在止血及手术防粘连类、组织封合及保护类、介入栓塞类、组织工程类等 生物材料领域拥有领先技术。目前拥有各类医疗器械产品 20 个，其中第三类医疗器械产品 8 个，3 个产品系国产独家产品；围绕 4 大生物材料领域共拥有主要在 研项目 11 ...

创业板投资风险提示 本次发行股票拟在创业板上市，创业板公司具有创新投入大、新旧产业 融合存在不确定性、尚处于成长期、经营风险高、业绩不稳定、退市风险高 等特点，投资者面临较大的市场风险。投资者应充分了解创业板的投资风险 及本公司所披露的风险因素，审慎作出投资决定。 国科恒泰（北京）医疗科技股份有限公司 （北京市北京经济技术开发区经海四路 25 号 6 号楼 5 层 501C 室） 首次公开发行股票并在创业板上市 招股说明书 保荐人（主承销商） （深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层） 招股说明书 声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 招股说明书 ...